On September 1, Enovis told the market it would spend €155 million on a surgical robot. Over the three days that followed, its CEO and its Chief Administrative Officer put roughly $450,000 of their own money into the stock the market was selling.
You read this morning that Damien McDonald and Oliver Engert both bought Enovis shares within pennies of a 52-week low. Tonight, let’s look at the business they were buying.
Three questions I’ll answer
| — |
What does Enovis actually make, and who writes the check for it? |
| — |
Why is one half of this company worth far more per sales dollar than the other half? |
| — |
What did €155 million buy — and why did the market treat it as a cost instead of an asset? |
I’ve been reading orthopedic device businesses for 25 years, and this one is simpler than its share price suggests. Let me show you the two halves. ↓
|
| |
| |
Elon Musk Just Did Something He's Never Done Before |
Take a look at this… |
|
|
This February, Elon spent millions to send a message to 125 million Americans. Most people ignored it. But Wall Street veteran Whitney Tilson couldn't stop thinking about it, and says what Elon was really saying explains everything about what's unfolding in America's economy right now. He's sharing his full analysis, free, here. |
|
|
|
|
|
|
Two Businesses, One Ticker
Enovis, listed in New York as ENOV, makes the hardware of human joints. It was an industrial conglomerate called Colfax until it sold the industrial arms and renamed itself in 2022. What remains runs as two businesses under one ticker. Prevention & Recovery sells braces, cold-therapy units, bone growth stimulators and physical-therapy equipment — the things handed to you after a torn knee ligament. Reconstructive sells the implants: artificial hips, knees, shoulders and ankles, plus the instruments a surgeon uses to fit them. The payer is a hospital or an insurer, not the patient.
Where the money is made
In the quarter ended July 3 the two halves were nearly the same size — Reconstructive at $295 million, Prevention & Recovery at $288 million. They are not the same quality of business. Gross margin is what is left of every sales dollar after the cost of making the product, before salaries and marketing.
|
Reconstructive gross margin, Q1 2026
|
69.1%
|
|
Prevention & Recovery gross margin, Q1 2026
|
53.8%
|
|
Blended adjusted gross margin, Q2 2026
|
61.7%
|
Fifteen points separate them, and the reason is who chooses. A brace is sold through distributors to a buyer who shops on price. An implant is chosen by a surgeon trained on one specific system, with instrument trays and hospital contracts built around it. Switching brands means relearning a procedure, so the cost of change sits with the doctor, not the patient. That is the moat. And last quarter the higher-margin half grew 8% while the lower-margin half fell 1%.
What €155 million bought
eCential Robotics is a Grenoble company that has spent more than fifteen years building robotic and computer-assisted surgery tools. Stryker, Zimmer Biomet and Johnson & Johnson’s DePuy Synthes all sell robotic systems to orthopedic surgeons. Enovis has never owned one. McDonald told investors on September 1 that a robot would reach the market within two years, knee first, shoulder after. The price is roughly €176 million in cash at closing plus up to €35 million in milestones, on top of debt already at 3.1 times annual adjusted profit.
Enovis guided to roughly a one percentage point drag on adjusted profit margin in 2027, with margin growth returning in 2028 alongside the first commercial sales. The market got a bill now and a benefit in two years, and priced the bill. BMO Capital cut its target to $27 from $30. The shares fell about a third in four weeks and set a 52-week low of $18.52. At the $19.15 McDonald paid, the whole company was valued near $1.1 billion — against 2026 revenue guidance of $2.31 to $2.37 billion.
NATE’S TAKE
Two things can be true at once. The robotics deal costs real money before it earns any, and a company carrying debt at 3.1 times profit has less room for that than one carrying half as much. The market is entitled to mark that down. But underneath it sits a business selling joint implants at a 69% gross margin to surgeons who do not switch easily, guided to $425 to $435 million of adjusted profit this year, valued near $1.1 billion where the CEO bought. McDonald and Engert had the same facts as everyone else. They also had their own money on the line, and Engert bought three days running at $20.32, then $19.46, then $18.80 — each cheaper than the last. That is not a forecast. It is a disclosure.
— Nate Fowler
After the Bell · Evening Special Edition
|
|
Tidak ada komentar:
Posting Komentar